[Molecular targeting drug of kinase inhibitors for castration resistant prostate cancer]

Research output: Contribution to journalReview articlepeer-review


Prostate cancer (PCa) is the most common cancer type in men. One of the most troublesome aspects of PCa is that androgen-dependent PCa inevitably progresses to highly aggressive and life-threatening castration resistant prostate cancer (CRPC). Kinases are key regulators of critical cancer processes such as cancer cell proliferation, invasion, differentiation or angiogenesis. Recent advances have shed light on molecular targeting inhibitors of kinases in CRPC. Aberrant expression of certain kinases has been implicated in the development and progression of PCa. Among them, some kinase inhibitors have emerged as promising drug targets for CRPC. In this review, we provide an overview of new therapeutic agents which arrived in an advanced stage of clinical testing, especially focusing on the targets of HGF/c-Met and PI3K/AKT/mTOR signaling pathways.

Original languageEnglish
Pages (from-to)2186-2192
Number of pages7
JournalNihon rinsho. Japanese journal of clinical medicine
Issue number12
Publication statusPublished - 2014 Dec 1
Externally publishedYes

ASJC Scopus subject areas

  • General Medicine


Dive into the research topics of '[Molecular targeting drug of kinase inhibitors for castration resistant prostate cancer]'. Together they form a unique fingerprint.

Cite this